Ivabradine Viatris

Active Ingredient:: Ivabradine Oxalate
Origin:: EU

Ivabradine Viatris (Ivabradine Oxalate)

Q: What conditions is Ivabradine Viatris used for?

Ivabradine Viatris is indicated for the treatment of chronic stable angina and for heart failure with reduced ejection fraction in patients who have an elevated resting heart rate despite optimal standard therapy.

Q: How does ivabradine work to lower heart rate?

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, slowing the pacemaker depolarisation that initiates each heartbeat. This reduces the heart rate without decreasing the force of cardiac contraction or affecting blood pressure.

Q: What is the usual dose of Ivabradine Viatris?

The prescribed dose of Ivabradine Viatris is determined by the treating physician based on the patient’s clinical condition, heart‑rate target, and tolerance. Dosage adjustments are made according to individual response and safety monitoring.

Q: Is Ivabradine Viatris safe during pregnancy or breastfeeding?

Safety data for ivabradine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the prescribing clinician.

Q: How do I order Ivabradine Viatris from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Ivabradine compare with beta‑blockers?

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and have broader cardiovascular effects, which may be advantageous or limiting depending on the patient’s profile.

Q: What are the storage requirements for Ivabradine Viatris?

Store Ivabradine Viatris at temperatures below 25 °C in its original container, protecting it from moisture and direct sunlight. Do not refrigerate or freeze the tablets.

Q: How is Ivabradine Viatris administered?

Ivabradine Viatris is taken orally, usually with a glass of water. The tablets should be swallowed whole and not split, crushed, or chewed unless otherwise directed by a healthcare professional.

Q: What are the most serious risks associated with Ivabradine Viatris?

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and persistent visual disturbances. Patients should be monitored for these events, especially when initiating therapy or adjusting the dose.

Q: Who should not use Ivabradine Viatris?

Ivabradine Viatris is contraindicated in patients with severe hypotension, sick sinus syndrome, second‑ or third‑degree atrioventricular block, acute myocardial infarction, or those taking strong CYP3A4 inhibitors that cannot be discontinued.

Ivabradine, the active ingredient in Ivabradine Viatris, is an If channel inhibitor presented as a tablet for oral use. It reduces heart rate in patients with chronic stable angina and heart failure with reduced ejection fraction.

GNH India supplies Ivabradine Viatris as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Viatris Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine acts on the cardiac If current to lower heart rate in specific cardiovascular conditions.

Chronic stable angina: decreases the frequency of angina attacks in patients whose resting heart rate remains above 70 bpm despite optimal therapy.
Heart failure with reduced ejection fraction: improves symptoms and reduces hospitalization risk in patients with left‑ventricular ejection fraction ≤35 % and elevated heart rate.
Elevated resting heart rate: helps achieve target heart rates in patients who remain tachycardic despite beta‑blocker treatment.

How It Works

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, which slows depolarisation of pacemaker cells. By reducing this inward sodium‑potassium current, the drug lowers spontaneous heart rate without affecting myocardial contractility, ventricular repolarisation, or blood pressure, providing rate control in angina and heart‑failure patients.

Side Effects

Common Side Effects

Visual disturbances (phosphenes): transient luminous phenomena.
Bradycardia: slower than normal heart rate.
Headache: mild to moderate intensity.
Dizziness or light‑headedness.
Fatigue or general weakness.
Blurred vision.

Serious or Rare Side Effects

Symptomatic bradycardia requiring medical attention.
Atrial fibrillation or other serious arrhythmias.
Severe hypotension.
Persistent visual disturbances.
Allergic reactions such as rash, pruritus, or angioedema.
Hepatic enzyme elevations.

Precautions & Warnings

Ivabradine should be used with careful clinical monitoring.

Heart rate monitoring: ensure resting heart rate remains above the minimum safe threshold.
Severe hypotension: avoid in patients with systolic blood pressure <90 mmHg.
Hepatic impairment: dose adjustment may be required in moderate to severe liver disease.
Concomitant bradycardic agents: use caution when combined with beta‑blockers, digoxin, or calcium‑channel blockers.
Sick sinus syndrome or atrioventricular block: contraindicated.
Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Ivabradine may interact with several medicines that affect heart rate or its metabolism.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels.
Other bradycardic agents (beta‑blockers, digoxin, non‑dihydropyridine calcium‑channel blockers): risk of excessive heart‑rate reduction.
Concomitant use with other If channel inhibitors: additive effect on heart rate.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may modestly raise ivabradine exposure.

CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
Antihypertensive drugs: monitor blood pressure and heart rate for additive effects.

Frequently Asked Questions

Ivabradine Viatris is indicated for the treatment of chronic stable angina and for heart failure with reduced ejection fraction in patients who have an elevated resting heart rate despite optimal standard therapy.

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, slowing the pacemaker depolarisation that initiates each heartbeat. This reduces the heart rate without decreasing the force of cardiac contraction or affecting blood pressure.

The prescribed dose of Ivabradine Viatris is determined by the treating physician based on the patient’s clinical condition, heart‑rate target, and tolerance. Dosage adjustments are made according to individual response and safety monitoring.

Safety data for ivabradine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the prescribing clinician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and have broader cardiovascular effects, which may be advantageous or limiting depending on the patient’s profile.

Store Ivabradine Viatris at temperatures below 25 °C in its original container, protecting it from moisture and direct sunlight. Do not refrigerate or freeze the tablets.

Ivabradine Viatris is taken orally, usually with a glass of water. The tablets should be swallowed whole and not split, crushed, or chewed unless otherwise directed by a healthcare professional.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and persistent visual disturbances. Patients should be monitored for these events, especially when initiating therapy or adjusting the dose.

Ivabradine Viatris is contraindicated in patients with severe hypotension, sick sinus syndrome, second‑ or third‑degree atrioventricular block, acute myocardial infarction, or those taking strong CYP3A4 inhibitors that cannot be discontinued.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.